On July 21, PegBio (02565.HK) rose 8.04% in regular trading, reaching HK$7.39, with turnover of HK$148 million.

On the news front, on July 17, PegBio, Shanghai Tenry Pharmaceutical, and Ali Health officially signed a strategic cooperation agreement in Hangzhou. The three parties will integrate pharmaceutical R&D, manufacturing, and digital health service resources to jointly advance the commercialization of core product Paidakang (visepegenatide injection). Paidakang has been approved for the treatment of type 2 diabetes in adults, is classified as an exclusive variety, and has passed the preliminary formal review for national medical insurance catalog adjustment.

Market focus has shifted from product approval to the pace of volume growth driven by hospital coverage and online-offline synergy. Under the cooperation framework, Tenry Pharmaceutical is responsible for nationwide commercial promotion, while Ali Health provides digital patient access channels. PegBio previously received HK$61 million as the first royalty payment from Tenry, with total milestone payments of approximately HK$140 million under the agreement targeting cumulative sales exceeding RMB 10 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)